{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:08:23Z","timestamp":1788883703961,"version":"build-2803163510"},"reference-count":20,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,8]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Monoclonal gammopathy of renal significance (MGRS) is a recognized clinical entity with multiple therapeutic approaches, often modeled after therapies used for multiple myeloma, including anti-CD38 antibodies, proteasome inhibitors, immunomodulatory agents, and autologous stem cell transplantation (ASCT). However, because of its rarity, the optimal use of newer agents, ASCT, and maintenance therapy remains poorly defined. We retrospectively analyzed 50 patients with biopsy-proven MGRS treated across 3 institutions. The most common histopathologic diagnosis was proliferative glomerulonephritis with monoclonal immunoglobulin deposits (72%). Median estimated glomerular filtration rate was 32 mL\/min (interquartile range, 17-51), and median 24-hour proteinuria was 3.28 g. A total of 37 patients received plasma cell (PC)\u2013directed therapy, and 8 patients received B-cell\u2013directed therapy. Common PC-directed induction regimens included daratumumab-based therapy (32.4%), CyBorD (cyclophosphamide, bortezomib, and dexamethasone; 29.7%), and bortezomib-dexamethasone (29.7%). Maintenance therapy was administered to 13 of 37 treated patients in the PC group (35.1%). With a median follow-up of 6.15 years, the median relapse-free survival (RFS) was 3.74 years in the PC group and 19 years in the B-cell group. Among PC-treated patients, RFS and overall survival (OS) did not significantly differ by induction regimen or use of ASCT. In contrast, maintenance therapy and induction duration &amp;gt;6 months were associated with significantly improved RFS, which remained significant on multivariate analysis. These findings suggest that maintenance therapy and prolonged treatment duration may improve disease control in MGRS and support further evaluation of extended treatment strategies to prevent renal damage and improve long-term outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018896","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:19:07Z","timestamp":1783531147000},"page":"6018-6026","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Maintenance therapy and improved relapse-free survival in patients with monoclonal gammopathy of renal significance"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8676-7840","authenticated-orcid":false,"given":"Francesca","family":"Cottini","sequence":"first","affiliation":[{"name":"1College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidharth","family":"Iyer","sequence":"additional","affiliation":[{"name":"1College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2918-8401","authenticated-orcid":false,"given":"Ana","family":"Avila-Rodriguez","sequence":"additional","affiliation":[{"name":"2Division of Hematology\/Oncology, University of Illinois Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9559-0282","authenticated-orcid":false,"given":"Karen","family":"Sweiss","sequence":"additional","affiliation":[{"name":"3Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8839-9380","authenticated-orcid":false,"given":"Chukwuemeka","family":"Uzoka","sequence":"additional","affiliation":[{"name":"2Division of Hematology\/Oncology, University of Illinois Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghia","family":"Chen","sequence":"additional","affiliation":[{"name":"4Department of Biostatistics, University of Illinois Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Ma","sequence":"additional","affiliation":[{"name":"4Department of Biostatistics, University of Illinois Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4304-2484","authenticated-orcid":false,"given":"Elvira","family":"Umyarova","sequence":"additional","affiliation":[{"name":"1College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Thakur","sequence":"additional","affiliation":[{"name":"1College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3332-0161","authenticated-orcid":false,"given":"Anjali","family":"Satoskar","sequence":"additional","affiliation":[{"name":"1College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3563-9475","authenticated-orcid":false,"given":"Pierre","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"5Department of Medicine, John Stroger Jr. Hospital of Cook County, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3687-2034","authenticated-orcid":false,"given":"Matias","family":"Sanchez","sequence":"additional","affiliation":[{"name":"2Division of Hematology\/Oncology, University of Illinois Chicago, Chicago, IL"},{"name":"5Department of Medicine, John Stroger Jr. Hospital of Cook County, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"issue":"2","key":"2026090811321232100_bib1","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.18632\/oncotarget.23412","article-title":"Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients","volume":"9","author":"Steiner","year":"2018","journal-title":"Oncotarget"},{"issue":"9","key":"2026090811321232100_bib2","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1093\/ndt\/gfy259","article-title":"The clinical implication of monoclonal gammopathies: monoclonal gammopathy of undetermined significance and of renal significance","volume":"34","author":"Batko","year":"2019","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"2026090811321232100_bib3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41408-023-00806-w","article-title":"Multiple myeloma with acute light chain cast nephropathy","volume":"13","author":"Leung","year":"2023","journal-title":"Blood Cancer J"},{"issue":"7","key":"2026090811321232100_bib4","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/ajh.26566","article-title":"Monoclonal gammopathy of renal significance (MGRS): real-world data on outcomes and prognostic factors","volume":"97","author":"Gozzetti","year":"2022","journal-title":"Am J Hematol"},{"issue":"1","key":"2026090811321232100_bib5","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1182\/hematology.2025000727","article-title":"Monoclonal gammopathy of renal significance from a hematologic perspective","volume":"2025","author":"Brailovski","year":"2025","journal-title":"Hematology"},{"key":"2026090811321232100_bib6","doi-asserted-by":"crossref","first-page":"103926","DOI":"10.1016\/j.critrevonc.2023.103926","article-title":"Monoclonal gammopathy of renal significance: multidisciplinary approach to diagnosis and treatment","volume":"183","author":"Karam","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"2026090811321232100_bib7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/bjh.17052","article-title":"Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance","volume":"193","author":"Kastritis","year":"2021","journal-title":"Br J Haematol"},{"issue":"12","key":"2026090811321232100_bib8","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1016\/j.ekir.2023.10.013","article-title":"The uncertainty puzzle of monoclonal gammopathy of renal significance without detectable clones","volume":"8","author":"Shah","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"8","key":"2026090811321232100_bib9","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group Consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"15","key":"2026090811321232100_bib10","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"a staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"issue":"7","key":"2026090811321232100_bib11","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/ajh.24738","article-title":"Renal outcomes in patients with AL amyloidosis: prognostic factors, renal response and the impact of therapy","volume":"92","author":"Kastritis","year":"2017","journal-title":"Am J Hematol"},{"issue":"10","key":"2026090811321232100_bib12","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1001\/jamaoncol.2024.2629","article-title":"Graded organ response and progression criteria for kidney immunoglobulin light chain amyloidosis","volume":"10","author":"Muchtar","year":"2024","journal-title":"JAMA Oncol"},{"issue":"1","key":"2026090811321232100_bib13","doi-asserted-by":"crossref","first-page":"2418339","DOI":"10.1080\/07853890.2024.2418339","article-title":"Maintenance therapy promotes profound organ and haematologic response in light-chain amyloidosis patients not undergoing autologous stem cell transplantation","volume":"56","author":"Wang","year":"2024","journal-title":"Ann Med"},{"issue":"2","key":"2026090811321232100_bib14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41408-020-0291-8","article-title":"Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis","volume":"10","author":"Dispenzieri","year":"2020","journal-title":"Blood Cancer J"},{"issue":"2","key":"2026090811321232100_bib15","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.kint.2021.10.017","article-title":"RNA-based immunoglobulin repertoire sequencing is a new tool for the management of monoclonal gammopathy of renal (kidney) significance","volume":"101","author":"Javaugue","year":"2022","journal-title":"Kidney Int"},{"issue":"2","key":"2026090811321232100_bib16","doi-asserted-by":"crossref","first-page":"100092","DOI":"10.1016\/j.bneo.2025.100092","article-title":"Improved survival with daratumumab-CyBorD compared with CyBorD as frontline therapy for AL amyloidosis","volume":"2","author":"Yohannan","year":"2025","journal-title":"Blood Neoplasia"},{"key":"2026090811321232100_bib17","unstructured":"Fervenza\n              F\n            \n          . Single-center phase 2 open-label trial evaluating efficacy and safety of daratumumab in treatment of patients with proliferative glomerulonephritis with monoclonal immune deposits and C3 glomerulopathy associated with monoclonal gammopathy. Clinical trial registration NCT03095118. Updated 31 August 2022. Accessed 28 June 2026.. https:\/\/clinicaltrials.gov\/study\/NCT03095118."},{"issue":"1","key":"2026090811321232100_bib18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.kint.2018.01.028","article-title":"Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft","volume":"94","author":"Said","year":"2018","journal-title":"Kidney Int"},{"issue":"7","key":"2026090811321232100_bib19","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1097\/TP.0000000000002577","article-title":"Recurrent proliferative glomerulonephritis with monoclonal immunoglobulin deposits in kidney allografts treated with anti-CD20 antibodies","volume":"103","author":"Buxeda","year":"2019","journal-title":"Transplantation"},{"issue":"9","key":"2026090811321232100_bib20","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/ndt\/gfaf036","article-title":"Autologous hematopoietic stem cell transplantation for non-AL amyloidosis monoclonal gammopathy of renal significance","volume":"40","author":"Liu","year":"2025","journal-title":"Nephrol Dial Transpl"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/17\/6018\/2542232\/blooda_adv-2025-018896-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/17\/6018\/2542232\/blooda_adv-2025-018896-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:32:19Z","timestamp":1788881539000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/17\/6018\/569588\/Maintenance-therapy-and-improved-relapse-free"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":20,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2026,9,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018896","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,8]]},"published":{"date-parts":[[2026,8,31]]}}}